Related Experiment Video
Updated: Mar 23, 2026

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
Published on: September 20, 2016
DNMT3A Haploinsufficiency Transforms FLT3ITD Myeloproliferative Disease into a Rapid, Spontaneous, and Fully
Sara E Meyer1, Tingting Qin2, David E Muench1
1Division of Immunobiology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio.
Unlabelled:
Cytogenetically normal acute myeloid leukemia (CN-AML) represents nearly 50% of human AML. Co-occurring mutations in the de novo DNA methyltransferase DNMT3A and the FMS related tyrosine kinase 3 (FLT3) are common in CN-AML and confer a poorer prognosis. We demonstrate that mice with Flt3-internal tandem duplication (Flt3(ITD)) and inducible deletion of Dnmt3a spontaneously develop a rapidly lethal, completely penetrant, and transplantable AML of normal karyotype. AML cells retain a single Dnmt3a floxed allele, revealing the oncogenic potential of Dnmt3a haploinsufficiency. FLT3(ITD)/DNMT3A-mutant primary human and murine AML exhibit a similar pattern of global DNA methylation associated with changes in the expression of nearby genes. In the murine model, rescuing Dnmt3a expression was accompanied by DNA remethylation and loss of clonogenic potential, suggesting that Dnmt3a-mutant oncogenic effects are reversible. Dissection of the cellular architecture of the AML model using single-cell assays, including single-cell RNA sequencing, identified clonogenic subpopulations that express genes sensitive to the methylation of nearby genomic loci and responsive to DNMT3A levels. Thus, Dnmt3a haploinsufficiency transforms Flt3(ITD) myeloproliferative disease by modulating methylation-sensitive gene expression within a clonogenic AML subpopulation.
Significance:
DNMT3A haploinsufficiency results in reversible epigenetic alterations that transform FLT3(ITD)-mutant myeloproliferative neoplasm into AML. Cancer Discov; 6(5); 501-15. ©2016 AACR.This article is highlighted in the In This Issue feature, p. 461.
Insights
DNMT3A haploinsufficiency combined with FLT3 mutations drives acute myeloid leukemia (AML) development. This transformation involves epigenetic changes that are reversible, offering potential therapeutic strategies for AML.
Area of Science:
- Hematology
- Cancer Biology
- Epigenetics
Background:
- Cytogenetically normal acute myeloid leukemia (CN-AML) accounts for nearly 50% of human AML cases.
- Co-occurring mutations in DNMT3A and FLT3 are prevalent in CN-AML and associated with poor prognosis.
Purpose of the Study:
- To investigate the role of DNMT3A haploinsufficiency in the development of FLT3-mutant AML.
- To explore the reversibility of epigenetic alterations and their impact on AML clonogenicity.
Main Methods:
- Development of a murine model with inducible Dnmt3a deletion and Flt3-internal tandem duplication (Flt3(ITD)).
- Analysis of DNA methylation patterns and gene expression in primary and murine AML.
- Utilized single-cell assays, including single-cell RNA sequencing, to dissect cellular architecture.
Main Results:
- Mice with Flt3(ITD) and Dnmt3a deletion developed a rapidly lethal, transplantable AML.
- DNMT3A haploinsufficiency was sufficient to drive AML development, and its effects were reversible upon restoring expression.
- Identified clonogenic AML subpopulations sensitive to DNMT3A levels and methylation changes.
Conclusions:
- DNMT3A haploinsufficiency transforms FLT3(ITD)-mutant myeloproliferative neoplasms into AML through reversible epigenetic alterations.
- Modulation of methylation-sensitive gene expression in specific subpopulations is key to DNMT3A's oncogenic effects.
- The reversibility of DNMT3A-mutant AML suggests potential therapeutic avenues.
More Related Videos
Related Concept Videos
Translation
Translation Produces the Building Blocks of Life
Proteins are...
Translation
Translation is the process of synthesizing proteins from the genetic information carried by messenger RNA (mRNA). Following transcription, it constitutes the final step in the expression of genes. This process is carried out by ribosomes, complexes of protein and specialized RNA molecules. Ribosomes, transfer RNA (tRNA), and other proteins produce a chain of amino acids—the polypeptide—as the end product of translation.
Translation Produces the Building Blocks of...
Abnormal Proliferation
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

